Kuwa Free! - Live Free!

NARecruitingINTERVENTIONAL
Enrollment

700

Participants

Timeline

Start Date

November 26, 2021

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
HIV InfectionsContraceptionDrug-drug Interaction
Interventions
DRUG

Cabotegravir/ Rilpivirine

"For initial injection participants will be given CABENUVA 600-mg/900-mg Kit: (single-dose vial of 600 mg/3 mL (200 mg/mL) cabotegravir , single-dose vial of 900 mg/3 mL (300 mg/mL) rilpivirin).~For subsequent injections participants will be given CABENUVA 400-mg/600-mg Kit: (single-dose vial of 400 mg/2 mL (200 mg/mL) cabotegravir, single-dose vial of 600 mg/2 mL (300 mg/mL) rilpivirine)~CABENUVA® is owned by or licensed to the ViiV Healthcare group of companies, GlaxoSmithKline Research Triangle Park, NC 27709"

DRUG

Etonogestrel (ETG) implant

Contraceptive progestin implants are thin rods inserted under the skin of a woman's arm

DRUG

Intramuscular depo-medroxyprogesterone acetate (IM DMPA)

DMPA (150 mg of depo-medroxyprogesterone acetate (MPA)/ml IMI) is the most commonly used injectable contraceptive worldwide

DRUG

Levonorgestrel

Contraceptive estrogen implants are thin rods inserted under the skin of a woman's arm

DRUG

NNRTI, PI, or INSTI-containing 1st or 2nd line ART regimens

ART that concurrently contains combinations of non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as efavirenz, and protease-inhibitors (PIs), such as atazanavir/ritonavir or lopinavir/ritonavir, or integrase inhibitors (INSTIs), such as raltegravir or dolutegravir

Trial Locations (1)

Unknown

RECRUITING

Academic Model Providing Access to Healthcare (AMPATH) Moi Teaching And Referral Hospital (MTRH), Eldoret

All Listed Sponsors
collaborator

Moi Teaching and Referral Hospital

OTHER

collaborator

Indiana University

OTHER

collaborator

University of Nebraska

OTHER

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

University of Alabama at Birmingham

OTHER